Search results
Results from the Go Local Guru Content Network
Biogen was founded in 1978 in Geneva as Biotechnology Geneva by several prominent biologists, including Kenneth Murray from the University of Edinburgh, Phillip Allen Sharp from the Massachusetts Institute of Technology, Walter Gilbert from Harvard University (Gilbert served as CEO during the start-up phase of Biogen), Heinz Schaller from the University of Heidelberg, and Charles Weissmann ...
Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug ...
By Manas Mishra and Mariam Sunny. (Reuters) -Biogen lifted its full-year profit forecast on Thursday due to cost cuts and better-than-expected sales of its various treatments, even as the U.S ...
Walter Gilbert was born in Boston, Massachusetts, on March 21, 1932, into a Jewish family, [6] the son of Emma (Cohen), a child psychologist, and Richard V. Gilbert, an economist. [4][7] When Gilbert was seven years old, the family moved to the Washington D.C. area so his father could work under Harry Hopkins on the New Deal brain trust.
Biogen continued developing its oral formulation of dimethyl fumarate from Fumapharm under the code name BG-12; it was approved, under the trade name Tecfidera, for the treatment of adults with relapsing forms of MS in March 2013. [21] Biogen priced the drug at $54,000 per year in the US. [16] It was approved in Europe in 2014. [3]
A biogenic substance is a product made by or of life forms. While the term originally was specific to metabolite compounds that had toxic effects on other organisms, [1] it has developed to encompass any constituents, secretions, and metabolites of plants or animals. [2] In context of molecular biology, biogenic substances are referred to as ...
Bioverativ Inc. is an American multinational biotechnology company that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia. [3] Bioverativ competes with Baxalta (acquired by Shire Plc in 2016 [4]), Pfizer and Novo Nordisk. [2] The company traded on the NASDAQ exchange under the ticker symbol ...
Tofersen was developed by Ionis Pharmaceuticals and was licensed to, and co-developed by, Biogen. [7] [8]The effectiveness of tofersen was evaluated in a 28-week, randomized, double-blind, placebo-controlled clinical study in 147 participants with weakness attributable to amyotrophic lateral sclerosis and a superoxide dismutase 1 (SOD-1) mutation confirmed by a central laboratory. [2]